Last reviewed · How we verify
pentoxyfilline
Pentoxyfilline, developed by the University of Zurich, is a marketed drug with a key composition patent expiring in 2028. The drug's primary strength lies in its established market presence and ongoing revenue generation. The primary risk is the potential increase in competition following the patent expiry in 2028.
At a glance
| Generic name | pentoxyfilline |
|---|---|
| Sponsor | University of Zurich |
| Modality | Small molecule |
| Therapeutic area | Other |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Effect of Tadalafil, Sildenafil and Pentoxyfylline on Frozen Embryo Transfer Outcomes (PHASE2, PHASE3)
- ICSI Using Pentoxifylline to Identify Viable Spermatozoa in Absolute Asthenozoospermia Patients (NA)
- Study of the Protective Effect of Mechanism of Pentoxyfilline After Major Liver Resection Under Inflow Occlusion (Pringle Manoeuvre) (PHASE4)
- Pentoxifylline and Late Onset Sepsis in Preterm Infants (PHASE3)
- Somatostatin, Octreotide, Pentoxyfilline in the Prevention of Post-ERCP Pancreatitis and Molecular Markers
- Role of 'Pentoxifylline and or IgM Enriched Intravenous Immunoglobulin in the Treatment of Neonatal Sepsis' (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- pentoxyfilline CI brief — competitive landscape report
- pentoxyfilline updates RSS · CI watch RSS
- University of Zurich portfolio CI